Introduction
============

The proof-of-concept that high amounts of antibodies exhibiting the same antigen specificity can be produced in a cost-effective manner has been first been provided in 1975 by the German biologist Georges Köhler and the Argentinian biochemist César Milstein.[@R1] This milestone discovery, which granted to Köhler and Milstein the 1984 Nobel Prize for Medicine or Physiology, not only has revolutionized countless experimental applications and diagnostic procedures, but also has generated a growing armamentarium of highly specific therapeutic agents.[@R2]^,^[@R3] Indeed, a large panel of monoclonal antibodies (mAbs) is nowadays approved by the US Food and Drug Administration (FDA) and other international regulatory agencies, including the European Medicines Agency (EMA), for the treatment of disorders as diverse as autoimmune diseases and cancer.[@R2]^,^[@R3] In 1997, rituximab, a chimeric (meaning that it contains both human and murine domains) molecule specific for the B-cell lineage marker CD20 was the first mAb to be licensed for use in cancer patients, i.e., individuals with non-Hodgkin's lymphoma (NHL) relapsing upon conventional chemotherapy.[@R4] Since then, no less than 15 distinct mAbs have been approved for the treatment of hematopoietic and solid neoplasms, encompassing: (1) mAbs that exert an antineoplastic activity as they primarily bind to proteins preferentially expressed on the surface of neoplastic, as opposed to non-malignant, cells; (2) mAbs that neutralize trophic signals provided by the tumor stroma; and (3) so-called immunostimulatory mAbs, i.e., mAbs that mediate therapeutic effects as they bind to, and hence modulate the activity of, cells of the immune system, de facto eliciting a novel or reactivating a pre-existing immune response against malignant cells. In 2 previous issues of *OncoImmunology*,[@R5]^,^[@R6] we have discussed the scientific rationale behind the use of mAbs, all types confounded, in cancer therapy, as well as the clinical development of (1) mAbs that have not yet been approved by the US FDA for use in humans, and (2) FDA-approved mAbs employed as off-label therapeutic interventions. As this area of clinical investigation is continuously expanding, here we will maintain the approach that we adopt in our Trial Watch series,[@R7]^-^[@R10] but we will restrict our attention on mAbs that mediate antineoplastic effects by primarily targeting cancer cells and/or the trophic support that they receive from the tumor stroma, which we cumulatively refer to as "tumor-targeting" mAbs ([Table 1](#T1){ref-type="table"}). Recent advances on the use of immunostimulatory antibodies in cancer therapy[@R11]^-^[@R16] will be discussed in the next Trial Watch.

###### **Table 1.** Tumor-targeting mAbs currently approved for cancer therapy.\*^,^\*\*

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  mAb                    Target   Approved   Type         Indication(s)
  ---------------------- -------- ---------- ------------ --------------------------------------------------------------------------------------------------
  Alemtuzumab            CD52     2001       Hzed IgG1    Chronic lymphocytic leukemia

  Bevacizumab            VEGF     2004       Hzed IgG1    Glioblastoma multiforme,\
                                                          colorectal, renal and lung cancer

  Brentuximab\           CD30     2011       C IgG1       Hodgkin\'s and anaplastic large cell\
  vedotin                                                 lymphoma (coupled to MMAE)

  Catumaxomab            CD3\     2009       M-R hybrid   Malignant ascites in patients\
                         EPCAM                            with EPCAM^+^ cancer

  Cetuximab              EGFR     2004       C IgG1       HNC and colorectal carcinoma

  Denosumab              RANKL    2011       H IgG2       Breast cancer, prostate carcinoma and giant cell tumors of the bone

  Gemtuzumab\            CD33     2000       Hzed IgG4    Acute myeloid leukemia\
  ozogamicin                                              (coupled with calicheamicin)

  Ibritumomab tiuxetan   CD20     2002       M IgG1       Non-Hodgkin lymphoma\
                                                          (coupled with ^90^Y or ^111^In)

  Panitumumab            EGFR     2006       H IgG2       Colorectal carcinoma

  Pertuzumab             HER2     2012       Hzed IgG1    Breast carcinoma

  Ofatumumab             CD20     2009       H IgG1       Chronic lymphocytic leukemia

  Rituximab              CD20     1997       C IgG1       Chronic lymphocytic leukemia\
                                                          and non-Hodgkin lymphoma

  Tositumomab            CD20     2003       H IgG1       Non-Hodgkin lymphoma\
                                                          (naked or coupled with ^131^I)

  Trastuzumab\           HER2     1998       Hzed IgG1    Breast carcinoma (naked or coupled to mertansine) and gastric or gastresophageal junction cancer
  (emtansine)                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** C, chimeric; EGFR, epidermal growth factor receptor; EPCAM, epithelial cell adhesion molecule; H, human; HNC, head and neck cancer; Hzed, humanized; M, murine; mAb, monoclonal antibody; MMAE, monomethyl auristatin E; R, rat; RANKL, receptor activator of NF-κB ligand; VEGF, vascular endothelial growth factor. \*by the US Food and Drug Administration or European Medicines Agency at the day of submission. \*\*updated from ref.[@R12]

For illustrative purposes, tumor-targeting mAbs can be sub-grouped into 6 non-mutually exclusive classes,[@R17] based on functional considerations: (1) mAbs that inhibit cancer cell-intrinsic signal transduction pathways that are required for survival and/or proliferation, such as cetuximab, a chimeric IgG1 specific for the epidermal growth factor receptor (EGFR), which is currently approved for the treatment of head and neck cancer and colorectal carcinoma (CRC);[@R18]^,^[@R19] (2) mAbs that activate cytotoxic receptors expressed by cancer cells (e.g., tumor necrosis factor receptor superfamily, member 10B, TNFRSF10B, best known as TRAILR2 or DR5), hence actively triggering their apoptotic demise, such as the fully human TRAILR2-specific IgG1 conatumumab;[@R20] (3) mAbs that bind (but not necessarily inhibit the activity of) tumor-associated antigens (TAAs) and exert antineoplastic effects as they engage effector mechanisms of innate immunity, including antibody-dependent cell-mediated cytotoxicity (ADCC),[@R3]^,^[@R21]^-^[@R24] antibody-dependent cellular phagocytosis (ADCP),[@R25] and complement-dependent cytotoxicity (CDC),[@R26]^,^[@R27] such as rituximab, which is widely employed for the treatment of chronic lymphocytic leukemia (CLL) and NHL;[@R28]^-^[@R30] (4) trifunctional (bispecific) mAbs, which can crosslink 2 distinct antigens (generally, one TAA and one T-cell marker) while preserving the capacity of activating immune effector functions via their constant fragment, such as catumaxomab, a chimeric (mouse and rat) mAb specific for CD3 and epithelial cell adhesion molecule (EPCAM) that is currently licensed for the therapy of malignant ascites in patients with EPCAM^+^ tumors;[@R31]^,^[@R32] (5) immunoconjugates, i.e., TAA-specific mAbs coupled to toxins or radionuclides, such as the CD20-targeting molecules ^90^Y-ibritumomab tiuxetan and ^131^I-tositumomab, which are nowadays used in the treatment of NHL;[@R33]^,^[@R34] and (6) mAbs that interfere with the trophic interaction between neoplastic cells and the tumor stroma, such as the vascular endothelial growth factor (VEGF)-directed mAb bevacizumab, which is currently approved for use in patients affected by CRC as well as lung and renal cancer.[@R35]^,^[@R36] It should be kept in mind that several tumor-targeting mAbs exert antineoplastic effects via multiple of these mechanisms. For instance, cetuximab not only inhibits EGFR signaling, but also triggers ADCC,[@R37] and has a direct immunostimulatory activity.[@R38]

Since the submission of our latest Trial Watch on this topic (October 2012),[@R5] the US FDA has approved bevacizumab for use in combination with fluoropyrimidine/irinotecan- or fluoropyrimidine/oxaliplatin-based chemotherapy for the treatment of patients with metastatic CRC whose disease has progressed in spite of first-line bevacizumab-based therapy.[@R39] Of note, bevacizumab had been licensed by the US FDA as first- or second-line therapeutic intervention in subjects affected by metastatic CRC as early as in 2004 and 2006, respectively.[@R40]^-^[@R42] During the last 13 mo, the US FDA has also extended the approval of denosumab, a human IgG2 specific for receptor activator of NF-κB ligand (RANKL), to unresectable giant cell tumors of the bone in adults and skeletally mature adolescents.[@R43]^,^[@R44] Besides being employed in postmenopausal women at risk for osteoporosis, denosumab is licensed by the US FDA since 2011 for use in patients at high risk of bone fracture as they undergo androgen-deprivation therapy for non-metastatic prostate cancer, or adjuvant aromatase inhibitor therapy for breast cancer.[@R45] On 2013, February, 22nd, the US FDA approved trastuzumab emtansine, a humanized IgG1 specific for *v-erb-b2* avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2) coupled to the cytotoxic agent mertansine, for use in women bearing HER2^+^ metastatic breast carcinoma who previously received naked trastuzumab (which is approved for use in breast carcinoma patients since 1998) and a taxane, separately or in combination.[@R46]^,^[@R47] Finally, no earlier than on 2013, September 30th, the US FDA granted accelerated approval to pertuzumab (a humanized IgG1 specific for HER2) for use in combination with trastuzumab and docetaxel for the neoadjuvant treatment of patients with HER2^+^, locally advanced, inflammatory, or early-stage breast cancer.[@R48] Of note, pertuzumab had previously (on 2012, June 8th) been licensed for use in combination with trastuzumab and docetaxel for the treatment of patients with metastatic HER2^+^ breast carcinoma who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.[@R49] However, the recent regulatory extension granted to this tumor-targeting mAB is relevant as pertuzumab in combination with trastuzumab and docetaxel has now become the first FDA-approved neoadjuvant treatment for patients with breast cancer (source <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm370393.htm>).

Update on Clinical Reports
==========================

Since the submission of our previous Trial Watch dealing with this topic (October 2012),[@R5] the preclinical and clinical development of mAbs for cancer therapy has proceeded at an unprecedented speed. Indeed, querying PubMed with the string "antibody AND cancer AND patients" as of 2013, October 21st returned more than 3200 entries indexed later than 2012, October 1st. Narrowing down the search to "antibody AND cancer AND patients AND trial" resulted in approximately 600 entries (source <http://www.ncbi.nlm.nih.gov/pubmed>). Although this figure (1) refers to mAbs all types confounded and (2) is expected to comprise a number of review articles, commentaries and false-positive hits (i.e., scientific reports that do not deal with the clinical development of mAb although they do contain all these keywords), it is representative of the huge interest that this therapeutic modality continues to attract. Obviously, a significant fraction of the clinical reports published during the last 13 mo on the use of tumor-targeting mAbs in cancer patients refers to the use of FDA-approved molecules as on-label interventions. This is the case of studies comparing experimental regimens to gold standard therapeutic approaches, when the latter involves a tumor-targeting mAb, as well as of studies that investigated whether some FDA-approved tumor-targeting mAbs can be safely and effectively administered at different doses and/or via different routes and/or according to alternative schedules. In line with the scope of our Trial Watch (see above), we will not consider these studies further. Rather, we will focus on experimental mAbs or FDA-approved mAbs employed as off-label interventions.

Experimental mAbs
-----------------

The results of no less than 33 clinical studies investigating the safety and efficacy of hitherto experimental tumor-targeting mAbs in cancer patients have been published during the last 13 mo ([Table 2](#T2){ref-type="table"}). The therapeutic paradigms investigated by these studies are relatively heterogeneous, encompassing the inhibition of cancer cell-intrinsic survival pathways, the active elicitation of endogenous signal transduction cascades with pro-apoptotic effects, the engagement of immune effectors, the selective delivery to neoplastic cells of cytotoxic agents or radionuclides as well as the blockade of trophic molecules produced by the tumor stroma and/or their receptors. Among the strategies that nowadays appear to attract more interest is the mAb-mediated inhibition of insulin-like growth factor 1 receptor (IGF1R), an anti-apoptotic signal transducer that is overexpressed by a large panel of tumors.[@R50] Thus, 3 distinct IGF1R-specific mAbs, namely, ganitumab (a fully human IgG1 also known as AMG 479),[@R51] cixutumumab (a fully human IgG1 also known as IMC-A12),[@R52] and AVE1642 (a humanized IgG1),[@R53]^,^[@R54] have recently been tested, either as a standalone intervention, either combined with conventional chemotherapeutic agents (e.g., docetaxel, doxorubicin, and gemcitabine), or given together with temsirolimus (an inhibitor of the mammalian target of rapamycin currently approved by FDA for the treatment of renal cell carcinoma),[@R55] in cohorts of patients affected by bone and soft tissue sarcomas,[@R56] pancreatic tumors,[@R57] locally advanced or metastatic breast carcinomas,[@R58] and advanced solid tumors.[@R59]^-^[@R61] In all these studies, anti-IGF1R antibodies were well tolerated and displayed promising clinic activity, at least in a subset of patients.

###### **Table 2.** Recently published clinical trials assessing the therapeutic profile of hitherto investigational tumor-targeting mAbs.^\*,\*\*^

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  mAb                               Target(s)                               Indication(s)                  Phase     Note                                                                      Ref.
  --------------------------------- --------------------------------------- ------------------------------ --------- ------------------------------------------------------------------------- ---------
  1D09C3                            HLA-DR                                  CLL\                           I         As single agent                                                           [@R94]
                                                                            Lymphoma                                                                                                           

  AGS-1C4D4                         PSCA                                    Pancreatic cancer              II        Combined with gemcitabine                                                 [@R95]

  AVE1642                           IGF1R                                   Solid tumors                   I         Combined with docetaxel                                                   [@R60]

  I                                 Combined with docetaxel,\               [@R59]                                                                                                             
                                    gemcitabine, erlotinib or doxorubicin                                                                                                                      

  Blinatumomab\                     CD3\                                    Acute lymphoblastic leukemia   II        As single agent or followed by HSCT                                       [@R96]
  (MEDI-538)                        CD19                                                                                                                                                       

  Carlumab (CNTO 888)               CCL2                                    Prostate cancer                II        As single agent                                                           [@R88]

  Solid tumors                      I                                       As single agent                [@R86]                                                                              

  Cixutumumab (IMC-A12)             IGF1R                                   Bone or\                       II        Combined with temsirolimus                                                [@R56]
                                                                            soft-tissue sarcomas                                                                                               

  Renal cell carcinoma              I                                       Combined with temsirolimus     [@R249]                                                                             

  Clivatuzumab tetraxetan           MUC1                                    Pancreatic cancer              I         Coupled with ^90^Y and combined\                                          [@R117]
                                                                                                                     with low-dose gemcitabine                                                 

  Conatumumab (AMG 655)             TRAILR2                                 Colorectal carcinoma           II        Combined with bevacizumab\                                                [@R65]
                                                                                                                     plus folinic acid-, 5-FU- and\                                            
                                                                                                                     oxaliplatin-based chemotherapy                                            

  Lung cancer                       II                                      Combined with paclitaxel\      [@R64]                                                                              
                                                                            plus carboplatin                                                                                                   

  Pancreatic cancer                 II                                      Combined with ganitumab\       [@R57]                                                                              
                                                                            and gemcitabine                                                                                                    

  Drozitumab (PRO95780)             TRAILR2                                 Colorectal carcinoma           Ib        Combined with bevacizumab\                                                [@R67]
                                                                                                                     plus folinic acid-, 5-FU- and\                                            
                                                                                                                     oxaliplatin-based chemotherapy                                            

  Farletuzumab (MORAb-003)          FOLR1                                   Ovarian carcinoma              II        As single agent or combined with platinum- or taxane-based chemotherapy   [@R97]

  GC33\                             GPC3                                    Hepatocellular carcinoma       I         As single agent                                                           [@R98]
  (RO5137382)                                                                                                                                                                                  

  Ganitumab (AMG 479)               IGF1R                                   Breast carcinoma               II        As single agent                                                           [@R58]

  Pancreatic cancer                 II                                      Combined with conatumumab\     [@R57]                                                                              
                                                                            and gemcitabine                                                                                                    

  Inotuzumab ozogamicin (CMC-544)   CD22                                    Non-Hodgkin's lymphoma         I/II      Combined with rituximab                                                   [@R99]

  Intetumumab (CNTO 95)             ITGA5                                   Prostate cancer                II        Combined with docetaxel\                                                  [@R100]
                                                                                                                     and prednisone                                                            

  KRN330                            GPA33                                   Colorectal cancer              I         As single agent                                                           [@R101]

  L19                               FN1                                     Solid tumors                   I/II      As a shuttle to deliver TNFα\                                             [@R120]
                                                                                                                     to the tumor vasculature                                                  

  Lexatumumab (HGS-ETR2)            TRAILR2                                 Solid tumors                   I         As single agent                                                           [@R66]

  Lintuzumab (SGN-33)               CD33                                    Acute myeloid leukemia         IIb       Combined with low-dose cytarabine                                         [@R108]

  MIK-β1 (MA1--35896)               IL2RB                                   T-LGL leukemia                 I         As single agent                                                           [@R93]

  Nimotuzumab (h-R3)                EGFR                                    NSCLC                          I         Combined with gefitinib                                                   [@R102]

  Obinutuzumab (GA101)              CD20                                    Non-Hodgkin's lymphoma         I         As single agent                                                           [@R103]

  Rilotumumab (AMG 102)             HGF                                     Prostate cancer                II        Combined with mitoxantrone\                                               [@R91]
                                                                                                                     plus prednisone                                                           

  Ramucirumab (IMC-1121B)           VEGFR2                                  Hepatocellular carcinoma       II        As single agent                                                           [@R77]

  Gastresophageal adenocarcinoma    III                                     As single agent                [@R76]                                                                              

  Lung cancer                       III                                     Combined with docetaxel        [@R78]                                                                              

  Trebananib (AMG 386)              ANGPT1\                                 Solid tumors                   I         As single agent                                                           [@R87]
                                    ANGPT2                                                                                                                                                     

  Volociximab\                      ITGA5\                                  NSCLC                          Ib        Combined with carboplatin and paclitax                                    [@R107]
  (M200)                            ITGB1                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** 5-FU, 5-fluorouracil; ANGPT, angiopoietin; CCL2, chemokine (C-C motif) ligand 2; CLL; chronic lymphocytic leukemia; EGFR, epidermal growth factor receptor; FN1, fibronectin 1; FOLR1, folate receptor 1 (adult); GPA33, glycoprotein A33; GPC3, glypican 3; HGF, hepatocyte growth factor; HSCT, hematopoietic stem cell transplantation; IGF1R, insulin-like growth factor 1 receptor; IL2RB, IL-2 receptor β; ITGA5, integrin α5; ITGB1, integrin β1; mAb, monoclonal antibody; MUC1, mucin 1; NSCLC, non-small cell lung carcinoma; PSCA, prostate stem cell antigen; T-LGL, T-cell large granular lymphocytic; TRAILR2, TNFα-related apoptosis-inducing ligand receptor 2; VEGFR2, vascular endothelial growth factor receptor 2. \*between 2012, October 1st and the day of submission. \*\*refers to mAbs that directly bind cancer cells or block trophic signals provided by the tumor stroma.

Another approach that has been investigated in several recent clinical studies is the therapeutic activation of TRAILR2.[@R62] Indeed, although both normal and malignant cells express TRAILR2, the latter appear to be more susceptible to TRAILR2 agonists than the former, for hitherto unclear reasons.[@R62]^,^[@R63] During the last 13 mo, the results of 5 distinct studies investigating the safety and clinical profile of TRAILR2-activating mAbs in cancer patients have been published.[@R57]^,^[@R64]^-^[@R67] In particular, these studies tested (1) conatumumab (a human IgG1 also known as AMG 655)[@R20]^,^[@R68]^,^[@R69] in combination with gemcitabine-based chemotherapy for the treatment of pancreatic cancer,[@R57] with paclitaxel plus carboplatin for the first-line treatment of advanced non-small-cell lung carcinoma (NSCLC),[@R64] or with bevacizumab plus a folinic acid-, 5-fluorouracil, and oxaliplatin-based chemotherapeutic regimen (generally known as mFOLFOX6) for the first-line treatment of metastatic CRC;[@R65] (2) drozitumab (a human IgG1 also known as PRO95780)[@R70]^,^[@R71] in combination with bevacizumab plus mFOLFOX6 as a first-line intervention against metastatic CRC;[@R67] and (3) lexatumumab (a human IgG1 also known as HGS-ETR2)[@R72]^-^[@R74] as a standalone intervention in pediatric patients affected by solid tumors.[@R66] In these clinical cohorts, TRAILR2-activating mAbs were well tolerated. The therapeutic potential of this approach, however, seems limited, as poor (if any) clinical responses have been documented among patients receiving TRAILR2 activating mAbs.

There are several means for blocking the trophic support that stromal cells normally provide to their malignant counterparts. By antagonizing VEGF receptor 2 (VEGFR2) signaling, ramucirumab (a human IgG1 also known as IMC-1121B), blocks perhaps the most prominent of these interactions, *i.e.*, neoangiogenesis.[@R75] Ramucirumab has recently been tested as a standalone intervention in patients affected by advanced gastric or gastresophageal junction adenocarcinoma and hepatocellular carcinoma,[@R76]^,^[@R77] as well as in combination with docetaxel for the treatment of stage IV NSCLC patients progressing upon one cycle of platinum-based therapy.[@R78] More frequently, however, mAbs are devised to block the crosstalk between neoplastic cells and their stroma by neutralizing soluble mediators. The precursor of this class of tumor-targeting mAbs is bevacizumab (which targets VEGF), but several other molecules operate in a similar fashion, including carlumab (a human IgG1 also known CNTO 888), which neutralizes chemokine (C-C motif) ligand 2 (CCL2);[@R79] trebananib (also known AMG 386), a peptibody (*i.e.*, a fusion between a biologically active peptide and the constant fragment of a mAb) that blocks angiopoietin 1 and 2;[@R80]^-^[@R82] and rilotumumab (a human IgG2 also known as AMG 102), which binds to---hence neutralizing---hepatocyte growth factor (HGF).[@R83]^-^[@R85] During the last 13 mo, carlumab and trebananib have been employed for dose-escalation studies in patients affected by advanced solid tumors,[@R86]^-^[@R88] while rilotumumab has been tested in combination with mitoxantrone (an anthracycline that induces the immunogenic demise of cancer cells)[@R8]^,^[@R89]^,^[@R90] and prednisone in patients with progressive, taxane-refractory castration-resistant prostate cancer.[@R91]^,^[@R92] All these agents were well tolerated, yet only trebananib was associated with durable antitumor activity in a fraction of patients.[@R87]

Among several other therapeutic strategies based on hitherto experimental tumor-targeting mAbs,[@R93]^-^[@R108] great interest is attracted by immunoconjugate-based regimens. This approach is very flexible, as it can be harnessed to shuttle chemicals,[@R109] radionuclides,[@R110] as well as biologically active factors (e.g., cytokines)[@R111]^-^[@R113] to virtually any cellular component of neoplastic lesions, provided that these components express (ideally in a restricted manner) an antigenic moiety on their surface.[@R114] Recently, ^90^Y-conjugated clivatuzumab tetraxetan, a humanized mAb specific for mucin 1 (MUC1, which is frequently overexpressed or aberrantly glycosylated in multiple carcinomas),[@R115]^,^[@R116] has been employed in combination with low-dose gemcitabine (an immunostimulatory therapeutic regimen)[@R11]^,^[@R12] in patients bearing advanced pancreatic neoplasms.[@R117] On a slightly different note, a tumor necrosis factor α (TNFα)-armed variant of L19, a human single chain variable fragment targeting the extra domain B (EDB) of fibronectin (which is predominantly expressed by the tumor-associated vasculature),[@R118]^,^[@R119] has been tested as a standalone therapeutic intervention in patients with advanced solid tumors.[@R120] Interestingly, these studies demonstrated some clinical activity for ^90^Y-conjugated clivatuzumab tetraxetan,[@R117] but not for the TNFα-L19 fusion.[@R120] However, the maximal tolerated dose of TNFα-L19 was not attained in this trial, leaving room for further tests at increased doses and/or in combination with conventional therapeutic regimens.

FDA-approved mAbs tested as off-label interventions
---------------------------------------------------

Testing FDA-approved drugs on indications for which they have not yet been licensed is advantageous in that safety concerns are generally limited. Accordingly, there is an intense wave of clinical investigation that aims at determining whether FDA-approved tumor-targeting mAbs employed as off-label interventions may provide clinical benefits to cancer patients. During the last 13 mo, the results of no less than 60 clinical trials of this type have been published in peer-reviewed scientific journals ([Table 3](#T3){ref-type="table"}). The largest fraction of these studies involved the VEGF-targeting mAb bevacizumab, which has been tested, most often in combination with conventional chemotherapy and/or targeted anticancer agents, in cohorts of patients affected by acute myeloid leukemia,[@R121] multiple myeloma,[@R122] head and neck squamous cell carcinoma (HNSCC),[@R123]^,^[@R124] breast carcinoma,[@R48]^,^[@R125]^-^[@R130] melanoma,[@R131] hepatocellular carcinoma,[@R132]^-^[@R136] pancreatic cancer,[@R137] ovarian carcinoma,[@R138]^-^[@R143] prostate cancer,[@R144] and several other advanced or metastatic solid tumors.[@R145]^-^[@R154] Moreover, ^89^Zr-conjugated bevacizumab has been investigated as a means to visualize neoplastic lesions by positron emission tomography (PET) in women with primary breast carcinomas, which often secrete high levels of VEGF.[@R155] In the context of a randomized Phase III clinical trial, the addition of bevacizumab to docetaxel and trastuzumab failed to improve the progression-free survival of HER2^+^ metastatic breast cancer patients.[@R156] Along similar lines, in patients with HER2^-^ metastatic or locally recurrent breast carcinoma, the combination of bevacizumab with capecitabine (a precursor of 5-fluorouracil) failed to meet the non-inferiority criterion as compared with a therapeutic regimen involving bevacizumab and paclitaxel (a microtubular poison of the taxane family).[@R127] Earlier, the addition of bevacizumab had been suggested to improve the efficacy of multiple taxanes, including paclitaxel and docetaxel, against breast carcinoma.[@R157]^,^[@R158] Thus, the clinical profile of specific, but not all, chemotherapeutics employed for the treatment of breast carcinoma may be ameliorated from the co-administration of bevacizumab. Nonetheless, on 2011, November 18th, the US FDA revoked the authorization that was given to bevacizumab for use in metastatic breast cancer patients (in combination with paclitaxel) in February 2008 (which was originally granted under the FDA accelerated approval program) (source <http://www.cancer.gov/cancertopics/druginfo>). Of note, plasmatic VEGF may constitute a predictive biomarker for bevacizumab efficacy among breast cancer patients.[@R125]^,^[@R156] A finding is being prospectively validated in the context of the MERiDiAN trial, a study in which patients will be treated with bevacizumab and paclitaxel upon stratification based on the circulating levels of short VEGF-A isoforms.[@R159] Finally, the addition of bevacizumab to cytotoxic chemotherapeutics including paclitaxel and carboplatin (a DNA-damaging platinum derivative),[@R160]^-^[@R162] has been associated with a small but quantifiable decrease in the quality of life of ovarian carcinoma patients.[@R141] This combinatorial regimen had previously been shown to prolong the disease-free survival of ovarian cancer patients (in particular individuals at high risk for progression) as compared with conventional paclitaxel- or carboplatin-based chemotherapy.[@R163] Thus, clinicians will have to carefully consider on a per-patient basis whether such a prolongation in disease-free survival is warranted in exchange of a decline in quality of life.

###### **Table 3.** Recently published clinical trials assessing the therapeutic profile of FDA-approved tumor-targeting mAbs employed as off-label anticancer interventions.^\*,\*\*^

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  mAb                              Target(s)                                                Indication(s)                                                             Phase   Note                           Ref.
  -------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------- ------- ------------------------------ ------
  Bevacizumab                      VEGF                                                     Angiosarcoma and epithelioid hemangioendotheliomas                        II      As a single agent              154

  Breast carcinoma                 n.a.                                                     Coupled to ^89^Zr as a diagnostic tool                                    155                                    

  II                               Combined with docetaxel plus capecitabine                126                                                                                                              

  II                               Combined with docetaxel plus cisplatin                   128                                                                                                              

  II                               Combined with gemcitabine                                129                                                                                                              

  II                               Combined with trastuzumab plus docetaxel                 48                                                                                                               

  III                              Combined with docetaxel                                  125                                                                                                              

  III                              Combined with capecitabine or paclitaxel                 130                                                                                                              

  III                              Combined with capecitabine or paclitaxel                 127                                                                                                              

  III                              Combined with trastuzumab plus docetaxel                 156                                                                                                              

  Cervical cancer                  II                                                       Combined with topotecan plus cisplatin                                    147                                    

  Colorectal carcinoma             II/III                                                   Combined with folinic acid, 5-FU,\                                        145                                    
                                                                                            oxaliplatin and irinotecan                                                                                       

  Endometrial carcinoma            II                                                       Combined with temsirolimus                                                150                                    

  Gastresophageal adenocarcinoma   II/III                                                   Combined with epirubicin,\                                                152                                    
                                                                                            cisplatin and capecitabine                                                                                       

  Hepatocellular carcinoma         n.a.                                                     Combined with erlotinib                                                   133                                    

  I                                Combined with rapamycin                                  132                                                                                                              

  II                               Combined with erlotinib                                  135                                                                                                              

  II                               Combined with erlotinib                                  134                                                                                                              

  II                               After transhepatic arterial chemoembolization            136                                                                                                              

  HNSCC                            II                                                       Combined with cisplatin plus IRMT                                         123                                    

  II                               Combined with cetuximab                                  124                                                                                                              

  Leukemia                         II                                                       Combined with cytarabine                                                  121                                    

  Melanoma                         II                                                       Combined with temozolomide or albumin-bound paclitaxel plus carboplatin   131                                    

  Multiple myeloma                 II                                                       Combined with bortezomib                                                  122                                    

  Ovarian carcinoma                n.a.                                                     As a single agent                                                         139                                    

  n.a.                             Combined with gemcitabine plus oxaliplatin               140                                                                                                              

  II                               Combined with docetaxel within 12\                       138                                                                                                              
                                   months of platinum-based therapy                                                                                                                                          

  II                               Combined with PLD                                        143                                                                                                              

  II                               Combined with albumin-bound paclitaxel                   142                                                                                                              

  III                              Combined with carboplatin plus paclitaxel                141                                                                                                              

  Pancreatic cancer                II                                                       Combined with gemcitabine plus 5-FU                                       137                                    

  Prostate cancer                  II                                                       Combined with docetaxel                                                   144                                    

  Urothelial carcinoma             II                                                       Combined with gemcitabine plus carboplatin                                149                                    

  Metastatic solid tumors          I                                                        Combined with vincristine,\                                               146                                    
                                                                                            irinotecan and temozolomide                                                                                      

  I                                Combined with albumin-bound\                             148                                                                                                              
                                   paclitaxel plus gemcitabine                                                                                                                                               

  I                                Combined with sorafenib plus low-dose cyclophosphamide   151                                                                                                              

  I                                Combined with temsirolimus\                              153                                                                                                              
                                   plus liposomal doxorubicin                                                                                                                                                

  Cetuximab                        EGFR                                                     Bone or\                                                                  II      As a single agent              179
                                                                                            soft-tissue sarcomas                                                                                             

  Breast carcinoma                 II                                                       Combined with cisplatin                                                   166                                    

  Cervical cancer                  I                                                        Combined with cisplatin                                                   177                                    

  Esophageal cancer                I                                                        As part of a chemoradiotherapeutic regimen                                168                                    

  II/III                           As part of a chemoradiotherapeutic regimen               167                                                                                                              

  Gastric cancer                   III                                                      Combined with capecitabine plus cisplatin                                 169                                    

  Lung cancer                      I                                                        Combined with bevacizumab plus erlotinib                                  170                                    

  II                               Combined with bevacizumab,\                              171                                                                                                              
                                   paclitaxel and carboplatin                                                                                                                                                

  Pancreatic cancer                n.a.                                                     Combined with gemcitabine plus IRMT                                       172                                    

  II                               Combined with gemcitabine plus oxaliplatin               173                                                                                                              

  I/II                             Combined with everolimus plus capecitabine               174                                                                                                              

  Prostate cancer                  II                                                       Combined with docetaxel                                                   176                                    

  Urothelial carcinoma             II                                                       Combined with paclitaxel                                                  178                                    

  Solid tumors                     n.a.                                                     As a single agent                                                         175                                    

  I                                As a carrier for doxorubicin-loaded immunoliposomes      180                                                                                                              

  Denosumab                        RANKL                                                    Lung cancer                                                               III     As a single agent              181

  Ofatumumab                       CD20                                                     Small lymphocytic lymphoma                                                I       As single agent                186

  Panitumumab                      EGFR                                                     Gastresophagic cancer                                                     III     Combined with epirubicin,\     185
                                                                                                                                                                              oxaliplatin and capecitabine   

  HNSCC                            III                                                      Combined with cisplatin plus 5-FU                                         182                                    

  Ovarian carcinoma                II                                                       Combined with PLD                                                         183                                    

  Pertuzumab                       HER2                                                     NSCLC                                                                     Ib      Combined with erlotinib        104

  Ovarian carcinoma                II                                                       Combined with carboplatin                                                 105                                    

  Rituximab                        CD20                                                     B-cell malignancies                                                       I       Combined with rIL-21           184
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** 5-FU, 5-fluorouracil; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; IL, interleukin; IMRT, intensity-modulated radiation therapy; mAb, monoclonal antibody; n.a., not available; NSCLC, non-small cell lung carcinoma; PLD, pegylated liposomal doxorubicin; r, recombinant; RANKL, receptor activator of NF-κB ligand; VEGF, vascular endothelial growth factor. \*between 2012, October 1st and the day of submission. \*\*refers to mAbs that directly bind cancer cells or block trophic signals provided by the tumor stroma.

Recently, the safety and efficacy of cetuximab as an off-label therapeutic intervention, most often in combination with conventional chemotherapeutic agents, chemical EGFR inhibitors (such as erlotinib),[@R164]^,^[@R165] or radiation therapy, have been investigated in patients affected by a large panel of neoplasms, including breast carcinoma,[@R166] esophageal and gastric cancer,[@R167]^-^[@R169] NSCLC,[@R170]^,^[@R171] pancreatic carcinoma,[@R172]^-^[@R174] and other solid tumors.[@R175]^-^[@R179] In addition, the tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded liposomes coupled to the antigen-binding fragment of cetuximab have been evaluated in patients with EGFR-overexpressing advanced solid tumors what were no longer amenable to standard treatments.[@R180] Only one of these studies was a large, open-label randomized Phase III trial, assessing the addition of cetuximab to capecitabine/cisplatin-based chemotherapy in patients with advanced gastric or gastresophageal junction cancer (EXPAND trial).[@R169] In this context, 904 patients (followed at 164 cancer centers in 25 distinct countries) were randomized at a 1:1 ratio to receive 3-wk cycles of twice-daily capecitabine (on days 1--14) plus intravenous cisplatin (on day 1), with or without weekly cetuximab (starting on day 1).[@R169] Grade 3--4 adverse events were significantly more frequent among patients treated with cetuximab than among individuals receiving chemotherapy only. Moreover, the addition of cetuximab to chemotherapy provided no additional benefits to advanced gastric cancer patients as compared with the use of capecitabine plus cisplatin alone.[@R169]

The results of a few other clinical trials testing FDA-approved tumor-targeting mAbs in off-label indications have been published during the last 13 mo.[@R181]^-^[@R186] In particular, denosumab has been shown to improve the overall survival of lung cancer patients with bone metastases as compared with zoledronic acid.[@R181] The addition of panitumumab (a EGFR-specific human IgG2 currently approved for the treatment of CRC)[@R187]^-^[@R189] to cisplatin- or 5-fluorouracil-based chemotherapy has been demonstrated to improve the progression-free survival (but not the overall) survival of unselected HNSCC patients.[@R182] Along similar lines, the combination of panitumumab with pegylated liposomal doxorubicin has been associated with clinical efficacy in patients with platinum-refractory ovarian carcinoma, though skin toxicity was considerable.[@R183] Conversely, panitumumab failed to improve the therapeutic profile of conventional chemotherapy in an unselected population of patients with advanced gastresophagic adenocarcinoma.[@R185] Finally, the co-administration of rituximab and recombinant interleukin (IL)-21 to patients with indolent B-cell malignancies has been reported to be well tolerated and clinically active, warranting further investigation.[@R184]

Additional studies
------------------

Although in our Trial Watch series we never discuss clinical studies that evaluate the therapeutic profile of anticancer agents employed as on-label interventions, a mention here goes to the CLEOPATRA trial, a randomized, double-blind, placebo-controlled, Phase 3 study investigating the safety and efficacy of pertuzumab,[@R49]^,^[@R190] in combination with trastuzumab and docetaxel, in patients with HER2^+^ first-line metastatic breast carcinoma.[@R106] In the context of this study, 808 women with HER2^+^ metastatic breast cancer who had not received previous chemotherapy or biological treatments (enrolled at 204 distinct cancer centers in 25 countries) were randomized at a 1:1 ratio to receive either pertuzumab, trastuzumab, and docetaxel or the same regimen with a matching placebo replacing pertuzumab.[@R106] At data cutoff (when the median follow-up was 30 mo for both groups), intention-to-treat analyses revealed a significant improvement in both disease-free and overall survival among patients receiving pertuzumab, trastuzumab, and docetaxel as compared with patients treated with trastuzumab and docetaxel only, with no marked differences in the incidence and severity of side effects.[@R106] As it stands, the first wave of results from the CLEOPATRA trial (which has been published in January 2012) underpinned the approval of pertuzumab for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2^+^ metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.[@R49] Conversely, the recent approval of pertuzumab for use in patients with HER2^+^, locally advanced, inflammatory, or early-stage breast cancer (see above) was supported by the results of the NeoSphere study, a Phase II, randomized clinical trial involving no less than 417 patients.[@R48]

Taken together, the findings of recently published clinical studies testing the safety and efficacy of tumor-targeting mAbs reinforce the notion that this approach is generally well tolerated and has the potential to elicit robust therapeutic responses, at least in subsets of patients. Among a huge amount of preclinical studies demonstrating the efficacy of tumor-targeting mAbs in a large panel of experimental paradigms (source <http://www.ncbi.nlm.nih.gov/pubmed>), we have found of particular interest the work by Boross and colleagues, demonstrating that IgAs and the corresponding Fc receptor (CD89) may be harnessed to achieve robust antineoplastic effects in vivo.[@R191] These observations pave the way to the development of novel tumor-targeting mAbs of the IgA, rather than IgG, isotype and strategies for the therapeutic targeting of CD89.

Update on Clinical Trials Testing Tumor-Targeting Monoclonal Antibodies
=======================================================================

When this Trial Watch was being redacted (October 2013), official sources listed 74 clinical trials launched after 2012, October 1st to evaluate the therapeutic profile of hitherto investigational tumor-targeting mAbs in cancer patients (16 studies) or the efficacy of FDA-approved tumor-targeting mAbs employed as off-label anticancer interventions (58 studies) (source <http://www.clinicaltrials.gov>).

Among the investigational tumor-targeting mAbs that continue to attract considerable clinical interest are nimotuzumab and necitumumab. Nimotuzumab (a humanized IgG1) and necitumumab (a fully human IgG1) target the EGFR and have been the subject of an intense wave of clinical investigation[@R192]^-^[@R205] During the last 13 mo, no less than 8 clinical trials have been launched to evaluate the safety and therapeutic potential of these EGFR-targeting mAbs, including 7 Phase I-II studies testing nimotuzumab or necitumumab in combination with conventional chemo(radio)therapeutic regimens in patients with breast carcinoma (NCT01939054); NSCLC (NCT01763788; NCT01769391; NCT01788566; NCT01861223), cervical carcinoma (NCT01938105) and rectal cancer (NCT01899118), as well as 1 Phase III trial assessing the therapeutic potential of nimotuzumab plus irinotecan (an inhibitor of topoisomerase I) in individuals with EGFR-overexpressing gastric or gastresophageal junction cancer (NCT01813253).

Alongside, multiple clinical studies have recently been initiated to investigate the therapeutic profile of a relatively heterogeneous group of investigational tumor-targeting mAbs. These mAbs include (1) BC8, a CD45-targeting murine IgG1 usually coupled to radionuclides,[@R206]^,^[@R207] which is now being tested (in its ^90^Y-conjugated form) together with combinatorial chemotherapy in patients with high-risk lymphoid malignancies allocated to undergo hematopoietic stem cells transplantation (NCT01921387); (2) blinatumomab, a bispecific T-cell engager (BiTE) targeting CD3 and CD19 (also known as MEDI-538),[@R96]^,^[@R208]^-^[@R210] now under evaluation as a standalone therapeutic measure in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (NCT01741792); (3) Ch14.18, a chimeric IgG1 specific for disialoganglioside GD2,[@R211]^-^[@R216] which is currently being assessed in combination with irinotecan and temozolomide (an alkylating agent) in young patients with relapsed or refractory neuroblastoma (NCT01767194); (4) conatumumab (see above), which is now being investigated in combination with a small SMAC peptidomimetic[@R217]^,^[@R218] in women with relapsed ovarian cancer (NCT01940172); (5) lintuzumab, a humanized IgG1 targeting the cell surface myelomonocytic differentiation antigen CD33,[@R219]^,^[@R220] which is currently being tested (as an ^225^Ac conjugate) in combination with cytarabine (an inhibitor of DNA synthesis) in old leukemia patients (NCT01756677); (6) SAR650984, a humanized IgG1 targeting CD38,[@R221] now under evaluation together with lenalidomide and dexamethasone[@R222] in patients with relapsed or refractory multiple myeloma (NCT01749969); and (7) TF2, a bispecific molecule that binds carcinoembryonic antigen (CEA) while providing a platform for the highly targeted delivery of a second, radionuclide (^68^Ga)-coupled peptide,[@R223]^-^[@R225] which is currently being tested as a diagnostic tool in subjects affected by HER2^-^ breast carcinoma (NCT01730612) or medullary thyroid carcinoma (NCT01730638) ([Table 4](#T4){ref-type="table"}).

###### **Table 4.** Clinical trials recently launched to evaluate the therapeutic profile of tumor-targeting monoclonal antibodies in investigational settings.^\*,\*\*^

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  mAb                                   Target(s)                 Indication(s)                                                    Phase                                                                 Status                   Note                                                          Ref.
  ------------------------------------- ------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------- ------------------------ ------------------------------------------------------------- -------------
  Alemtuzumab                           CD52                      Hematological malignancies                                       I/II                                                                  Not yet recruiting       In combination with genetically modified T cells              NCT01875237

  Peripheral T-cell lymphoma            II                        Completed                                                        As a consolidation regimen upon cyclophosphamide-based chemotherapy   NCT01806337                                                                            

  BC8                                   CD45                      Hematological malignancies                                       I/II                                                                  Not yet recruiting       Followed by BEAM\                                             NCT01921387
                                                                                                                                                                                                                                  chemotherapy and ASCT                                         

  Bevacizumab                           VEGF                      Brain tumors                                                     II                                                                    Recruiting               As single agent                                               NCT01767792

  Breast carcinoma                      0                         Not yet recruiting                                               As ^89^Zr-bevacizumab radiotracer                                     NCT01894451                                                                            

  II                                    Not yet recruiting        Combined with carboplatin, cyclophosphamide or paclitaxel        NCT01898117                                                                                                                                                  

  II                                    Not yet recruiting        Combined with eribulin                                           NCT01941407                                                                                                                                                  

  II                                    Not yet recruiting        Combined with cyclophosphamide, doxorubicin and paclitaxel       NCT01959490                                                                                                                                                  

  II                                    Recruiting                Combined with paclitaxel                                         NCT01722968                                                                                                                                                  

  Glioma                                I/II                      Recruiting                                                       Combined with temozolomide\                                           NCT01891747                                                                            
                                                                                                                                   and vitamin C                                                                                                                                                

  II                                    Recruiting                Combined with radiation therapy                                  NCT01743950                                                                                                                                                  

  Lymphoma                              II                        Recruiting                                                       Combined with gemcitabine-based chemotherapy                          NCT01921790                                                                            

  Melanoma                              II                        Not yet recruiting                                               Combined with paclitaxel-based chemotherapy                           NCT01879306                                                                            

  II                                    Not yet recruiting        Combined with ipilimumab                                         NCT01950390                                                                                                                                                  

  MM                                    n.a.                      Recruiting                                                       As ^89^Zr-bevacizumab radiotracer                                     NCT01859234                                                                            

  Ovarian cancer                        II                        Not yet recruiting                                               Combined with trabectedin ± carboplatin                               NCT01735071                                                                            

  II                                    Recruiting                Combined with carboplatin\                                       NCT01739218                                                                                                                                                  
                                                                  and paclitaxel                                                                                                                                                                                                                

  II                                    Recruiting                Combined with paclitaxel                                         NCT01770301                                                                                                                                                  

  II                                    Recruiting                Combined with carboplatin\                                       NCT01838538                                                                                                                                                  
                                                                  and paclitaxel                                                                                                                                                                                                                

  II                                    Recruiting                Combined with carboplatin\                                       NCT01847677                                                                                                                                                  
                                                                  and paclitaxel                                                                                                                                                                                                                

  III                                   Active not recruiting     Combined with carboplatin\                                       NCT01837251                                                                                                                                                  
                                                                  and PLD                                                                                                                                                                                                                       

  III                                   Not yet recruiting        Combined with carboplatin and gemcitabine or paclitaxel or PLD   NCT01802749                                                                                                                                                  

  Reproductive\                         II                        Recruiting                                                       Combined with carboplatin\                                            NCT01770171                                                                            
  tract cancers                                                                                                                    and paclitaxel                                                                                                                                               

  II                                    Recruiting                Combined with gemcitabine\                                       NCT01936974                                                                                                                                                  
                                                                  ± platinum based chemotherapy                                                                                                                                                                                                 

  II                                    Terminated with results   Followed by abraxane infusion                                    NCT01821859                                                                                                                                                  

  Rhabdomyosarcoma                      II                        Recruiting                                                       Combined with cyclophosphamide-based chemotherapy                     NCT01871766                                                                            

  Sarcoma                               I                         Recruiting                                                       Combined with doxorubicin\                                            NCT01746238                                                                            
                                                                                                                                   and radiation therapy                                                                                                                                        

  Sarcoma and neuroectodermal tumors    II                        Not yet recruiting                                               Combined with cyclophosphamide-based chemotherapy                     NCT01946529                                                                            

  Advanced or metastatic solid tumors   I                         Not yet recruiting                                               Combined with lurbinectedin\                                          NCT01831089                                                                            
                                                                                                                                   and paclitaxel                                                                                                                                               

  I                                     Recruiting                Combined with tivantinib                                         NCT01749384                                                                                                                                                  

  I                                     Recruiting                As single agent                                                  NCT01847118                                                                                                                                                  

  II                                    Not yet recruiting        As single agent                                                  NCT01898130                                                                                                                                                  

  II                                    Recruiting                Combined with cisplatin\                                         NCT01951482                                                                                                                                                  
                                                                  and pemetrexed                                                                                                                                                                                                                

  Blinatumomab                          CD3\                      DLBCL                                                            II                                                                    Recruiting               As single agent                                               NCT01741792
                                        CD19                                                                                                                                                                                                                                                    

  Brentuximab vedotin                   CD30                      AML                                                              I                                                                     Recruiting               Combined with immunogenic chemotherapy                        NCT01830777

  DLBCL                                 II                        Recruiting                                                       Combined with cyclophosphamide-based chemotherapy                     NCT01925612                                                                            

  Germ cell tumors                      II                        Not yet recruiting                                               As single agent                                                       NCT01851200                                                                            

  Lymphoma                              I/II                      Recruiting                                                       Combined with rituximab                                               NCT01805037                                                                            

  III                                   Recruiting                Combined with cyclophosphamide-based chemotherapy                NCT01777152                                                                                                                                                  

  Mast cell leukemia                    n.a.                      Not yet recruiting                                               As single agent                                                       NCT01807598                                                                            

  Peripheral T-cell lymphoma            n.a.                      Not yet recruiting                                               As single agent                                                       NCT01841021                                                                            

  Catumaxomab                           CD3\                      Gastric peritoneal carcinomatosis                                II                                                                    Recruiting               As single agent                                               NCT01784900
                                        EPCAM                                                                                                                                                                                                                                                   

  Ovarian cancer                        II                        Recruiting                                                       As single agent                                                       NCT01815528                                                                            

  Cetuximab                             EGFR                      Brain tumors                                                     I/II                                                                  Recruiting               Combined with bevacizumab                                     NCT01884740

  Esophageal cancer\                    II                        Recruiting                                                       Combined with cisplatin,\                                             NCT01787006                                                                            
  Gastric cancer                                                                                                                   5-FU and radiotherapy                                                                                                                                        

  II                                    Completed                 Combined with carboplatin,\                                      NCT01904435                                                                                                                                                  
                                                                  paclitaxel and radiotherapy                                                                                                                                                                                                   

  Advanced solid tumors                 I                         Recruiting                                                       Combined with erlotinib                                               NCT01727869                                                                            

  I                                     Recruiting                Combined with irinotecan\                                        NCT01787500                                                                                                                                                  
                                                                  and vemurafenib                                                                                                                                                                                                               

  Ch14.18                               GD2                       Neuroblastoma                                                    II                                                                    Recruiting               Combined with irinotecan\                                     NCT01767194
                                                                                                                                                                                                                                  and temozolomide                                              

  Conatumumab                           TRAILR2                   Reproductive\                                                    I                                                                     Not yet recruiting       Combined with birinapant                                      NCT01940172
                                                                  tract cancers                                                                                                                                                                                                                 

  Denosumab                             RANKL                     NSCLC                                                            II                                                                    Not yet recruiting       As single agent                                               NCT01951586

  Lintuzumab                            CD33                      Leukemia                                                         I/II                                                                  Recruiting               Combined with cytarabine                                      NCT01756677

  Necitumumab                           EGFR                      NSCLC                                                            I/II                                                                  Recruiting               Combined with cisplatin\                                      NCT01763788
                                                                                                                                                                                                                                  and gemcitabine                                               

  II                                    Recruiting                Combined with carboplatin\                                       NCT01769391                                                                                                                                                  
                                                                  and paclitaxel                                                                                                                                                                                                                

  II                                    Recruiting                Combined with cisplatin and gemcitabine                          NCT01788566                                                                                                                                                  

  Nimotuzumab                           EGFR                      Breast carcinoma                                                 II                                                                    Not yet recruiting       Combined with capecitabine\                                   NCT01939054
                                                                                                                                                                                                                                  and docetaxel                                                 

  Cervical cancer                       II                        Recruiting                                                       Combined with chemoradiotherapy                                       NCT01938105                                                                            

  Gastric cancer                        III                       Recruiting                                                       Combined with irinotecan                                              NCT01813253                                                                            

  NSCLC                                 I/II                      Not yet recruiting                                               Combined with afatinib                                                NCT01861223                                                                            

  Rectal cancer                         II                        Recruiting                                                       Combined with radiotherapy, capecitabine and oxaliplatin              NCT01899118                                                                            

  Ofatumumab                            CD20                      Leukemia                                                         II                                                                    Not yet recruiting       Combined with cyclophosphamide\                               NCT01762202
                                                                                                                                                                                                                                  and fludarabine                                               

  NHL                                   I                         Recruiting                                                       Combined with rIL-18                                                  NCT01768338                                                                            

  Panitumumab                           EGFR                      Anal cancer                                                      II                                                                    Recruiting               Combined with capecitabine, mitomycin and radiotherapy        NCT01843452

  Bladder cancer                        II                        Recruiting                                                       Combined with carboplatin\                                            NCT01916109                                                                            
                                                                                                                                   and gemcitabine                                                                                                                                              

  Pertuzumab                            HER2                      Gastric cancer\                                                  III                                                                   Recruiting               Combined with capecitabine, cisplatin, 5-FU and trastuzumab   NCT01774786
                                                                  Gastresophageal cancer                                                                                                                                                                                                        

  Rituximab                             CD20                      B-cell malignancies                                              I                                                                     Recruiting               Combined with a PI3K inhibitor                                NCT01905813

  Hodgkin\'s lymphoma                   0                         Not yet recruiting                                               Combined with brentuximab vedotin                                     NCT01900496                                                                            

  Neuroblastoma                         III                       Recruiting                                                       Combined with dexamethasone                                           NCT01868269                                                                            

  Prostate cancer                       0                         Recruiting                                                       As single agent                                                       NCT01804712                                                                            

  SAR650984                             CD38                      MM                                                               I                                                                     Recruiting               Combined with lenalidomide\                                   NCT01749969
                                                                                                                                                                                                                                  and dexamethasone                                             

  TF2                                   CEA                       Breast cancer                                                    I/II                                                                  Recruiting               As single agent                                               NCT01730612

  Medullary thyroid carcinoma           I/II                      Recruiting                                                       As single agent                                                       NCT01730638                                                                            

  Trastuzumab                           HER2                      Bladder cancer                                                   II                                                                    Active, not recruiting   Combined with carboplatin,\                                   NCT01828736
                                                                                                                                                                                                                                  cisplatin and gemcitabine                                     

  Recurrent or metastatic tumors        II                        Recruiting                                                       Combined with lapatinib                                               NCT01771458                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** 5-FU, 5-fluorouracil; AML, acute myeloid leukemia; ASCT, autologous stem cell transplantation; BEAM, carmustine + etoposide + cytarabine + melphalan; CEA, carcinoembryonic antigen; DLBCL, diffuse large B-cell lymphoma; EGFR, epidermal growth factor receptor; EPCAM, epithelial cell adhesion molecule; IL, interleukin; mAb, monoclonal antibody; MM, multiple myeloma; n.a., not available; NHL, non-Hodgkin\'s lymphoma; NSCLC, non-small cell lung carcinoma; PI3K, phosphoinositide-3-kinase; PLD, pegylated liposomal doxorubicin; r, recombinant; RANKL, receptor activator of NF-κB ligand; TRAILR2, TNFα-related apoptosis-inducing ligand receptor 2; VEGF, vascular endothelial growth factor. \*between 2012, October 1st and the day of submission. \*\*refers to hitherto investigational tumor-targeting mAbs as well as to FDA-approved tumor-targeting mAbs employed as off-label interventions.

For obvious safety reasons, the largest fraction of clinical trials initiated during the last 13 mo to test tumor-targeting mAbs aims at determining whether FDA-approved molecules might exert therapeutic effects in off-label indications. Thus, bevacizumab is currently being tested as a diagnostic tool (in its ^89^Zr-conjugated form) or as a therapeutic intervention, most frequently in combination with standard chemo(radio)therapeutic regimens, in patients with hematological malignancies (NCT01859234; NCT01921790), various forms of sarcoma (NCT01746238; NCT01871766; NCT01946529), glioma (NCT01743950; NCT01891747), breast carcinoma (NCT01722968; NCT01894451; NCT01898117; NCT01941407; NCT01959490), melanoma (NCT01879306; NCT01950390), ovarian carcinoma (NCT01735071; NCT01739218; NCT01770301; NCT01802749; NCT01837251; NCT01838538; NCT01847677), neoplasms of the reproductive tract (NCT01770171; NCT01821859; NCT01936974), and other (advanced or metastatic) solid tumors (NCT01749384; NCT01767792; NCT01831089; NCT01847118; NCT01898130; NCT01951482; NCT01946529). Brentuximab vedotin, an anti-CD30 monomethyl auristatin E (MMAE) conjugate approved for the treatment of relapsed Hodgkin's lymphoma and relapsed systemic anaplastic large cell lymphoma,[@R226]^,^[@R227] is being investigated, either as a single therapeutic agent or combined with (often cyclophosphamide-based) chemotherapy, in patients affected by acute myeloid leukemia (NCT01830777), mast cell leukemia or systemic mastocytosis (NCT01807598); DLBCL or other forms of lymphoma (NCT01777152; NCT01805037; NCT01841021; NCT01925612), and CD30^+^ germ cell tumors (NCT01851200). The clinical profile of cetuximab, invariably in combination with chemotherapy or multimodal therapy, is being evaluated in subjects bearing esophageal or gastric carcinoma (NCT01787006; NCT01904435), brain neoplasms (NCT01884740) or other advanced solid tumors (NCT01727869; NCT01787500). Rituximab, given as a standalone therapeutic regimen or combined with brentuximab vedotin, dexamethasone or INCB040093 (an orally available inhibitor of the δ isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3-kinases)[@R228]^,^[@R229] is under investigation for its therapeutic potential in cohorts of individuals with various B-cell malignancies (NCT01905813), Hodgkin's lymphoma (NCT01900496), neuroblastoma-associated opsoclonus myoclonus syndrome (a rare neurological disorder of unclear origin)[@R230] (NCT01868269), and prostate carcinoma (NCT01804712). The clinical profile of trastuzumab, in combination with either conventional chemotherapy or lapatinib (a tyrosine kinase inhibitor currently approved in HER2^+^ breast carcinoma patients),[@R231] is being assessed in patients bearing bladder neoplasms (NCT01828736) or other solid tumors (NCT01771458). Pertuzumab is being tested in combination with trastuzumab as a first-line therapeutic intervention in patients with gastric or gastresophageal carcinoma (NCT01774786). Catumaxomab is now being evaluated as a standalone therapeutic agent in patients with gastric peritoneal carcinomatosis (NCT01784900) or ovarian carcinoma (NCT01815528). Denosumab plus standard chemotherapy is under investigation as a first-line intervention against metastatic NSCLC (NCT01951586). Ofatumumab, a human IgG1 targeting CD20 that is approved by FDA for the treatment of CLL,[@R232]^,^[@R233] is currently being tested, in combination with cyclophosphamide-based chemotherapy or human recombinant IL-18,[@R234] in patients with other forms of leukemia (NCT01762202) or NHL (NCT01768338). Alemtuzumab, a CD52-specific humanized IgG1 that is licensed for use in CLL patients,[@R235]^,^[@R236] is being evaluated as a consolidation regimen upon cyclophosphamide-based chemotherapy in patients with peripheral T-cell lymphoma (NCT01806337) or in combination with donor lymphocyte infusions in subjects with multiple hematological malignancies (NCT01875237). Finally, panitumumab, an EGFR-specific humanized IgG2 currently licensed for use in CRC patients,[@R237]^,^[@R238] is under investigation as a therapeutic measure against anal cancer (NCT01843452) and bladder carcinoma (NCT01916109) ([Table 4](#T4){ref-type="table"}).

As for the clinical trials listed in our previous Trial Watches dealing with this topic,[@R5]^,^[@R6] the following studies have changed status: NCT00560794, NCT00848926, NCT00866047, and NCT00986674, now listed as "Active, not recruiting"; NCT00563680, NCT00947856, NCT00778167, and NCT00838201, now listed as "Completed"; NCT01614795, now listed as "Temporarily closed to accrual"; NCT00385827, NCT01335204, and NCT01513317, now listed as "Terminated"; and NCT01034787, whose status is now "Unknown." NCT01513317, comparing siltuximab (a chimeric mAb that neutralizes IL-6, also known as CNTO 328)[@R239]^,^[@R240] plus best supportive care to placebo plus best supportive care in anemic patients with low/intermediate-risk myelodysplastic syndrome, has been stopped after the interim analysis, based on lack of efficacy (although there were no safety concerns). Conversely, the reasons underlying the suspension of NCT01614795 and the termination of both NCT00385827 and NCT01335204 are not available. Among "Active, not recruiting" and "Completed" studies, (preliminary or definitive) results appear to be available for NCT00560794;[@R241] NCT00778167; NCT00838201; NCT00848926; NCT00866047; NCT00947856;[@R242] and NCT00986674 (source <http://www.clinicaltrials.gov>).

Concluding Remarks
==================

The interest of clinicians in harnessing the specificity of mAbs for cancer therapy remains very high, as demonstrated by the consistent number of clinical trials that have been initiated during the last 13 mo to test this immunotherapeutic paradigm in oncological settings. As discussed here, a large fraction of these studies involves tumor-targeting mAbs, i.e., mAbs that primarily bind to malignant cells or interrupt the trophic support provided to developing tumors by the stroma. Such an intense wave of clinical development is paralleled by the relatively frequent approval by FDA of (1) novel tumor-targeting mAbs, or (2) novel oncological indications for previously licensed molecules. As some (but not all) tumor-targeting mAbs exert antineoplastic effects by engaging immune effector functions, it will be interesting to see whether and in which circumstances the clinical benefits of mAbs can be improved by combining these immunotherapeutic agents with broad or targeted immunostimulatory interventions, including selected cytokines,[@R111]^,^[@R112] Toll-like receptor agonists,[@R243]^-^[@R245] immunogenic chemotherapy;[@R246]^-^[@R248] and irradiation.[@R110]
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ADCC

:   antibody-dependent cell-mediated cytotoxicity

ADCP

:   antibody-dependent cellular phagocytosis

CDC

:   complement-dependent cytotoxicity

CLL

:   chronic lymphocytic leukemia

CRC

:   colorectal carcinoma

DLBCL

:   diffuse large B-cell lymphoma

EGFR

:   epidermal growth factor receptor

EMA

:   European Medicines Agency

EPCAM

:   epithelial cell adhesion molecule

FDA

:   Food and Drug Administration

HNSCC

:   head and neck squamous cell carcinoma

IGF1R

:   insulin-like growth factor 1 receptor

IL

:   interleukin

mAb

:   monoclonal antibody

MMAE

:   monomethyl auristatin E

NHL

:   non-Hodgkin's lymphoma

NSCLC

:   non-small cell lung carcinoma

TAA

:   tumor-associated antigen

TNFα

:   tumor necrosis factor α

VEGF

:   vascular endothelial growth factor
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